Advertisement

PharmacoEconomics & Outcomes News

, Volume 819, Issue 1, pp 24–24 | Cite as

Lenalidomide cost effective in newly diagnosed multiple myeloma

Clinical study
  • 9 Downloads

References

  1. 1.
    Zhou Z-Y, et al. Cost-Effectiveness Analysis of Lenalidomide for Maintenance Therapy after Autologous Stem Cell Transplant (ASCT) in Newly Diagnosed Multiple Myeloma (NDMM) Patients: A United States Payer Perspective. 60th Annual Meeting and Exposition of the American Society of Hematology : (plus poster) abstr. 3535, 1 Dec 2018. Available from: URL: https://ash.confex.com/ash/2018/webprogram/Paper112942.html
  2. 2.
    Uyl-de Groot CA, et al. Lenalidomide As Maintenance Treatment for Patients with Newly Diagnosed Multiple Myeloma Post-Autologous Stem Cell Transplantation: A Pharmacoeconomic Assessment in the Netherlands. 60th Annual Meeting and Exposition of the American Society of Hematology : (plus poster) abstr. 3555, 1 Dec 2018. Available from: URL: https://ash.confex.com/ash/2018/webprogram/Paper112826.html

Copyright information

© Springer Nature Switzerland AG 2019

Personalised recommendations